{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'TABLE OF CONTENTS', 'SIGNATURES OF SPONSOR', '3', 'SIGNATURE OF INVESTIGATOR', '4', 'DOCUMENT HISTORY', '5', 'SUMMARY OF CHANGES', '5', 'SYNOPSIS', '18', 'TABLE OF CONTENTS', '33', 'LIST OF TABLES', '37', 'LIST OF FIGURES', '37', 'LIST OF APPENDICES', '37', 'LIST OF ABBREVIATIONS', '38', 'DEFINITION OF TERMS', '40', '1. INTRODUCTION', '43', '1.1.', 'Background Information', '43', '1.2.', 'Investigational Medicinal Product', '44', '1.3.', 'Standard of Care and Rationale for Use of ARGX-113', '45', '1.4.', 'Benefit-Risk Assessment', '47', '2.', 'TRIAL OBJECTIVES', '48', '2.1.', 'Primary Objective', '48', '2.2.', 'Secondary Objectives', '48', '2.3.', 'Tertiary Objective', '49', '3.', 'TRIAL ENDPOINTS', '49', '3.1.', 'Primary Endpoint', '49', '3.2.', 'Secondary Endpoints', '49', '3.3.', 'Tertiary Endpoints', '50', '4.', 'INVESTIGATIONAL PLAN', '51', 'argenx BVBA', 'Confidential', 'Page 33 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '4.1.', 'Summary of Trial Design', '51', '4.2.', 'Discussion of Trial Design', '54', '4.3.', 'Selection of Trial Population', '56', '4.3.1.', 'Inclusion Criteria', '56', '4.3.2.', 'Exclusion Criteria', '57', '4.4.', 'Early Discontinuation', '58', '4.4.1.', 'Early Discontinuation from Trial', '59', '4.4.2.', 'Early Discontinuation from Randomized Treatment', '59', '4.4.3.', 'Temporary Interruption from Randomized Treatment', '60', '4.4.4.', 'Missed Doses', '60', '4.5.', 'Roll-Over to Follow-on Trial', '60', '4.6.', 'Protocol Deviations', '61', '4.7.', 'Screen Failures, Rescreening, and Retesting', '61', '4.8.', 'Early Termination of Trial or Site', '62', '4.9.', 'End of Trial definition', '62', '5.', 'TRIAL PROCEDURES', '62', '5.1.', 'Informed Consent', '63', '5.2.', 'Screening', '63', '5.3.', 'Randomization', '64', '5.4.', 'Treatment Cycle', '66', '5.4.1.', 'Treatment Period', '66', '5.4.2.', 'Follow-up Period', '67', '5.5.', 'Inter Treatment Cycle Period', '68', '5.6.', 'End of Treatment', '69', '5.7.', 'Safety and Disease Severity Follow-up Period for Patients who Discontinued', 'Early from Randomized Treatment', '69', '5.8.', 'End of Study and Early Discontinuation (EoS/ED) Visit', '70', '5.9.', 'Unscheduled Visit', '70', '6.', 'TRIAL TREATMENTS', '71', '6.1.', 'Treatments Administered', '71', 'argenx BVBA', 'Confidential', 'Page 34 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '6.2.', 'Identity of Investigational Medicinal Products', '71', '6.3.', 'Packaging and Labeling', '72', '6.4.', 'Storage of Investigational Medicinal Products', '72', '6.5.', 'Method of Assigning Patients to Treatment Group', '72', '6.6.', 'Timing of Dose for Each Patient', '73', '6.7.', 'Blinding', '73', '6.8.', 'Prior Treatments and Concomitant Medications', '73', '6.8.1.', 'Prohibited Medications during the Trial', '74', '6.8.2.', 'Rescue Therapy', '74', '6.9.', 'Medical Care of Patients after End of Study', '74', '6.10.', 'Treatment Compliance', '75', '6.11.', 'Handling Missed Doses of the Investigational Medicinal Product', '75', '6.12.', 'Accountability of Investigational Medicinal Product', '75', '6.13.', 'Storage of Blood Samples in the Trial', '75', '7.', 'TRIAL ASSESSMENTS', '75', '7.1.', 'Efficacy and Quality of Life', '75', '7.1.1.', 'Myasthenia Gravis-Activities of Daily Living', '76', '7.1.2.', 'Quantitative Myasthenia Gravis', '76', '7.1.3.', 'Myasthenia Gravis Composite', '76', '7.1.4.', '15-Item Quality of Life Scale for Myasthenia Gravis', '77', '7.1.5.', 'EQ-5D-5L', '77', '7.2.', 'Safety', '77', '7.2.1.', 'Adverse Events', '78', '7.2.2.', 'Clinical Laboratory Evaluations', '84', '7.2.3.', 'Vital Signs, Physical Examination, and ECG', '85', '7.2.4.', 'Suicidality Assessment', '85', '7.2.5.', 'Medical and Surgical History', '86', '7.2.6.', 'Data Safety Monitoring Board (DSMB)', '86', '7.2.7.', 'Visit Reminder/Subject ID Card', '86', '7.3.', 'Pharmacokinetics (PK)', '86', 'argenx BVBA', 'Confidential', 'Page 35 of 110']\n\n###\n\n", "completion": "END"}